[EN] NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS UTILES EN TANT QU'INHIBITEURS DE S100
申请人:ACTIVE BIOTECH AB
公开号:WO2015177367A1
公开(公告)日:2015-11-26
A compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
Inhibition and Dispersion of Bacterial Biofilms with 2-Aminobenzimidazole Derivatives
申请人:BLACKWELL Helen
公开号:US20130136782A1
公开(公告)日:2013-05-30
Compounds described herein inhibit biofilm formation or disperse pre-formed biofilms of Gram-negative bacteria. Biofilm-inhibitory compounds can be encapsulated or contained in a polymer matrix for controlled release. Coatings, films, multilayer films, hydrogels, microspheres and nanospheres as well as pharmaceutical compositions and disinfecting compositions containing biofilm-inhibitory compounds are also provided. Methods for inhibiting formation of biofilms or dispersing already formed biofilms are provided. Methods for treating infections of gram-negative bacteria which form biofilms, particularly those of
Pseudomonas
and more particularly
P. aeruginosa.
The invention relates to a method for preventing or treating a disease or disorder that is associated with the MrgX2 receptor. The invention also relates to MrgX2 antagonists and physiologically acceptable salts thereof. The invention also relates to pharmaceutical compositions and dosage forms comprising an MrgX2 antagonist.
Ambident heterocyclic reactivity: Alkylation of 2-substituted-4-methylbenzimidazoles
作者:M.Rezaul Haque、Malcolm Rasmussen
DOI:10.1016/s0040-4020(01)80708-0
日期:1994.5
inducing changes in alkylation regioselectivity. The combined results are consistent with dominant ‘steric approach control’ for the alkylations, where the magnitude of the steric effect is critically dependent on the length of the developing N - - - C bond in the variable geometry SN2 alkylation transition states involved. Unequal steric effects of 2-substituents on N1 and N3 alkylations and their variation
确定了对4-甲基-,2,4-二甲基-,2-氨基-4-甲基-,2-氯-4-甲基-,2-乙氧基-4-甲基-苯并咪唑和4-甲基的烷基化的区域选择性。甲基苯并咪唑酮(作为二甲基甲酰胺中的阴离子)与各种伯烷基化剂。在可比较的条件下,这些N 1 / N 3区域选择性与这些热杂环阴离子的苄基化的二级速率常数(苄基氯/二甲基甲酰胺/ 30°)相关。改变所述烷基化剂,[R “CH 2氯,导致沿S的松密轴移动Ñ 2过渡态的结构,并产生在区域选择性显着变化。沿晚期S N的变化由改变2- R -4-甲基苯并咪唑阴离子中的2-取代基引起的2轴在诱导烷基化区域选择性变化方面效果不佳。结合的结果与烷基化的主要“空间方法控制”相一致,其中空间效应的大小主要取决于所涉及的可变几何结构S N 2烷基化过渡态中正在发展的N--C键的长度。2-取代基对N 1和N 3烷基化的不等空间效应及其随烷基化剂的变化是通过调用氮烷基化位点的
Amino-benzimidazole derivatives
申请人:E. R. Squibb & Sons, Inc.
公开号:US03981886A1
公开(公告)日:1976-09-21
Amino-benzimidazole derivatives of the structure ##SPC1## Are provided which are useful as anti-inflammatory agents. In addition, a method for preparing such compounds, pharmaceutical compositions containing such compounds, and methods for using such pharmaceutical compositions in the treatment of inflammation are taught.